CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
250 mg DCS +2 moredrug
Likely dose
250 mg DCSfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02376257
NCT02376257Phase 2Completed
CompareCT.gov

Improving Therapeutic Learning in Depression: Proof of Concept

Boston University Charles River Campus·interventional·Posted Mar 3, 2015·Updated Sep 19, 2018

In Brief

A Phase 2 clinical trial evaluating 250 mg DCS, 100 mg Modafinil, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments. This study is concerned with the development of one such novel treatment, the augmentation of exposure-based cognitive-behavior therapy (CBT) with d-cycloserine (DCS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 3, 2015
Enrollment StartSep 16, 2014
Primary CompletionApr 21, 2017
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.3 years ago

Interventions

250 mg DCSdrug

Drug

100 mg Modafinildrug

Drug

Placebodrug

Drug